Literature DB >> 6580527

Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia.

C R Bartram, A de Klein, A Hagemeijer, T van Agthoven, A Geurts van Kessel, D Bootsma, G Grosveld, M A Ferguson-Smith, T Davies, M Stone.   

Abstract

The localization of cellular oncogenes near the break points of tumour-specific chromosomal aberrations suggests an involvement of these genes in the generation of neoplasms. Recently, we demonstrated the translocation of the human cellular homologue (c-ab1) of the transforming sequence of Abelson murine leukaemia virus (A-MuLV) from chromosome 9 to the Philadelphia chromosome (Ph1) in chronic myelocytic leukaemia (CML). In an attempt to investigate the significance of this translocation in the pathogenesis of CML, we have now studied two CML patients with complex translocations, t(9; 11; 22) and t(1; 9; 22), and two CML Ph1-negative patients with apparently normal karyotypes. In addition to using blot hybridization with human c-ab1 probes and DNA from rodent: CML cell hybrids as before, we have used in situ hybridization of these probes directly to metaphase chromosomes of CML patients. These studies show that the c-ab1 gene is translocated in Ph1-positive but not in Ph1-negative CML patients. CML without the Ph1 chromosome seems to be a distinct entity with a different origin, and this view is supported by clinical observations including correlations which reveal a poorer prognosis.

Entities:  

Mesh:

Year:  1983        PMID: 6580527     DOI: 10.1038/306277a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  140 in total

Review 1.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

Authors:  B J Druker; N B Lydon
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.

Authors:  T Kuwabara; M Warashina; T Tanabe; K Tani; S Asano; K Taira
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

Review 3.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

4.  Quantitative intra-individual monitoring of BCR-ABL transcript levels in archival bone marrow trephines of patients with chronic myeloid leukemia.

Authors:  Oliver Bock; Ulrich Lehmann; Hans Kreipe
Journal:  J Mol Diagn       Date:  2003-02       Impact factor: 5.568

5.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; Z Arlin; S Advani; S L Allen; J Goldman; D Snyder; A Foti; M Cline
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

6.  Molecular genetic analysis of DNA obtained from fixed, air dried or paraffin embedded sources.

Authors:  K Grünewald; J Lyons; T E Hansen-Hagge; J W Janssen; H Feichtinger; C R Bartram
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

Review 7.  Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Authors:  Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

Review 8.  The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers.

Authors:  Yu Zhang; Monica Gostissa; Dominic G Hildebrand; Michael S Becker; Cristian Boboila; Roberto Chiarle; Susanna Lewis; Frederick W Alt
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

9.  Chromosomal localization of the human Thy-1 gene.

Authors:  J van Rijs; V Giguère; J Hurst; T van Agthoven; A Geurts van Kessel; S Goyert; F Grosveld
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

Review 10.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.